文献速递白血病造血干细胞移植与细胞治疗

二次急性髓系白血病的单倍体移植结局:欧洲血液与骨髓移植学会急性白血病工作组(ALWP)研究

Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study.
PubMed 文献 · Am J Hematol · 2018-04-11

该研究基于欧洲血液与骨髓移植学会(EBMT)急性白血病工作组注册库,分析2006至2016年154例接受未处理单倍体造血干细胞移植的二次急性髓系白血病患者。移植时69例处于首次完全缓解、85例为活动性疾病。多因素分析显示预处理强度、年龄、体能状态或移植物来源对结局无差异;活动性疾病与更高的复发率及更差的LFS、OS、GRFS相关;与移植后环磷酰胺相比,抗胸腺球蛋白T细胞去除导致更高的NRM和更差的LFS、OS、GRFS。

要点

  • 单倍体移植是二次急性髓系白血病在缺乏全合供者时的可行选择。
  • 移植时活动性疾病与更高的复发率和更差的LFS、OS、GRFS相关。
  • 抗胸腺球蛋白T细胞去除较移植后环磷酰胺的NRM更高、生存更差。

核心结论

  • 单倍体造血干细胞移植是二次急性髓系白血病在无匹配移植供者时的可行替代方案。

研究设计与样本

  • 基于欧洲血液与骨髓移植学会(EBMT)急性白血病工作组注册库,识别2006年至2016年接受单倍体造血干细胞移植的154例二次急性髓系白血病患者。

主要发现

  • 移植时中位年龄60岁,从诊断至移植中位时间5个月;69例处于首次完全缓解,85例为活动性疾病。
  • 57例(38.0%)接受清髓性预处理,97例(62.0%)接受减低强度预处理。
  • 多因素分析显示预处理强度、年龄、体能状态或移植物来源对复发率、非复发死亡、无白血病生存、总生存或无GVHD/无复发生存均无差异。
  • 与移植时处于完全缓解的患者相比,活动性疾病与更高的复发率和更差的无白血病生存、总生存及无GVHD/无复发生存相关。
  • 与移植后环磷酰胺相比,抗胸腺球蛋白T细胞去除导致更高的非复发死亡和更差的无白血病生存、总生存及无GVHD/无复发生存(HR分别为2.25、2.01、2.16、1.73,P值均<.05)。

临床怎么用

  • 作者认为单倍体造血干细胞移植是二次急性髓系白血病在无匹配移植供者时的可行替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary acute myeloid leukemia (sAML) traditionally has inferior outcomes compared to de novo AML. Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy. This study analyzes the outcomes for unmanipulated haploidentical HCT (haploHCT) for sAML using the Acute Leukemia Working Party (ALWP) registry of the European Society for Blood and Marrow Transplantation (EBMT). We identified 154 patients with sAML who underwent haploHCT from 2006 to 2016. Median age at HCT was 60 years with time from diagnosis to HCT 5 months. At transplantation, 69 patients were in first CR and 85 had active disease. Fifty-seven (38.0%) patients underwent myeloablative conditioning and 97 (62.0%) reduced intensity conditioning (RIC) conditioning. Multivariate analysis showed that there was no difference in RI, nonrelapse mortality (NRM), leukemia free survival (LFS), overall survival (OS), or GVHD-free/relapse free survival (GRFS) for conditioning intensity, age, performance status, or graft source. Active disease was associated with higher RI and inferior LFS, OS, and GRFS compared with patients in CR at time of transplant. T-cell depletion with anti-thymoglobulin resulted in higher NRM and inferior LFS, OS, and GRFS compared to post-transplant cyclophosphamide (PTCy) (HR 2.25, 2.01, 2.16, and 1.73, respectively with P values <.05). Our data shows that haploHCT is a feasible alternative for sAML when matched transplantation is unavailable.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Li Z, Labopin M, Ciceri F, et al. Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study. Am J Hematol. 2018. PMID: 29536560. doi:10.1002/ajh.25087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。